P21 (5mg)

€116.00

Size: 5mg
Contents: P21
Form: Lyophilized powder
Purity: >99%
SKU: P-P21

Categories: Peptides for Sale, Research Peptides for Sale

Description
Reviews (0)

P21 (5mg) – Synthetic Neurotrophic Research Peptide

P21 (5mg), also known as P021, is a synthetic peptide derivative developed from a biologically active region of ciliary neurotrophic factor (CNTF). It has attracted research interest in neurobiology, neurogenesis, neuronal plasticity, learning and memory, and experimental models of neurodegenerative disease.

The referenced Core Peptides product is supplied as 5mg of lyophilised P21 powder with a stated purity of >99%. The product is designated for research, laboratory and analytical purposes only.

Preclinical research has investigated P21/P021 in animal models, particularly in relation to hippocampal neurogenesis, neuronal differentiation, synaptic plasticity and cognitive performance.

These findings remain experimental and should not be interpreted as evidence of an established human treatment. Current evidence does not establish human efficacy or safety.

What Is P21?

P21, commonly written as P021, is a synthetic neurotrophic peptide designed from a short active region of CNTF. It should not be confused with p21^Cip1 / CDKN1A, the unrelated cell-cycle regulatory protein. The research compound discussed here is P021, a CNTF-derived peptide mimetic.

CNTF is a naturally occurring cytokine belonging to the neurotrophic factor family. It has been studied for its involvement in neuronal survival, differentiation and nervous-system development. Researchers developed smaller peptide sequences based on biologically active regions of CNTF in an effort to investigate neurotrophic signalling in a more compact molecular format.

Research reviews describe P021 as an adamantane-modified derivative of a short CNTF-derived sequence. The modification was designed to improve properties such as stability and the ability of the molecule to access the central nervous system.

P21 (5mg) Product Specifications

Specification	Details
Product Name	P21
Alternative Name	P021 / Peptide 021
Quantity	5mg
Form	Lyophilised powder
Stated Purity	>99%
Peptide Class	Synthetic CNTF-derived neurotrophic peptide mimetic
Reported Sequence	Ac-DGGL-adamantanylglycine-NH₂
Reported Molecular Formula	C₃₀H₅₄N₆O₅
Reported Molecular Weight	578.3 g/mol
Research Focus	Neurobiology, neurogenesis, neuronal plasticity and cognitive research
Intended Use	Research, laboratory and analytical purposes only

The quantity, lyophilised format and stated purity are taken from the referenced Core Peptides listing. The supplier’s listed chemical information should be checked against the applicable batch-specific certificate of analysis before analytical or experimental use.

P21 and CNTF Research

Ciliary neurotrophic factor (CNTF) is a signalling protein that has been extensively studied for its effects on neuronal survival and differentiation. CNTF itself is a relatively large protein, which led researchers to investigate smaller fragments capable of reproducing selected aspects of its biological activity.

Research described in scientific reviews identified an active CNTF-derived sequence and progressively shortened it to smaller peptide structures. P021 was subsequently developed by incorporating an adamantylated glycine component into the shortened sequence.

This approach provides researchers with a useful model for studying how structural modifications can affect peptide stability, transport and neurotrophic signalling.

P21 and Neurogenesis Research

Neurogenesis refers to the formation of new neurons from neural progenitor cells. Adult hippocampal neurogenesis has been a significant area of neuroscience research because the hippocampus is involved in learning, memory and other cognitive processes.

Preclinical research has investigated P021 in relation to the proliferation and differentiation of adult hippocampal progenitor cells. Scientific reviews report that P021 increased markers associated with neural progenitor proliferation and neuronal maturation in experimental models.

These observations provide a basis for further laboratory research into neurotrophic signalling and neural plasticity. However, findings in rodents cannot be assumed to translate directly into equivalent effects in humans.

P21 and BDNF Signalling

Brain-derived neurotrophic factor (BDNF) is an important neurotrophin involved in neuronal survival, differentiation, synaptic function and plasticity.

Research reviews have reported that P021 may influence neurogenic processes partly through changes in BDNF-related signalling. Experimental studies have associated P021 with increased BDNF expression and downstream effects on neural progenitor cells and synaptic markers.

The proposed relationship between P021 and BDNF remains an area for mechanistic research. It should not be interpreted as proof that P21 can improve cognition or treat neurological disease in humans.

P21 and Hippocampal Research

The hippocampus is a brain structure extensively involved in memory formation, spatial learning and related cognitive processes. Because of these functions, it has become an important model system for studying neurogenesis and synaptic plasticity.

Animal research involving P021 has examined changes in hippocampal progenitor-cell proliferation, neuronal differentiation and markers associated with synaptic function. Core Peptides similarly describes experimental research in murine models involving hippocampal neurogenesis, cognition and neuronal differentiation.

For researchers, P21 therefore provides a molecular tool for investigating relationships between neurotrophic signalling, hippocampal biology and behavioural outcomes in controlled experimental models.

P21 and Synaptic Plasticity

Synaptic plasticity describes the ability of neural connections to change their strength and functional properties in response to activity. It is a major subject of research into learning, memory and neurological function.

Preclinical studies have reported that P021 can influence markers associated with synaptic plasticity and neuronal maturation. Reviews of the research describe changes in synaptic-marker expression alongside increased formation and integration of new neurons in experimental models.

These findings make P21 relevant to experimental investigations of neurotrophic signalling and neural-network adaptation.

P21 and Cognitive Research

P21 has been investigated in animal models in which researchers assessed learning and memory alongside biological changes in the hippocampus.

Core Peptides describes preclinical findings involving potential improvements in cognition and hippocampal neuronal processes in murine models, while published reviews report improved cognitive performance alongside neurogenic and synaptic changes in mice.

Such findings are scientifically relevant but remain preclinical. There is currently insufficient evidence to claim that P21 improves memory, learning or cognitive performance in humans.

P21 and Neurodegenerative Disease Research

Because neurogenesis, neurotrophic signalling and synaptic plasticity are relevant to neurodegenerative research, P21 has been investigated in experimental models of neurological disease.

Research has included animal models associated with Alzheimer’s disease and other forms of neurological dysfunction. Studies have examined outcomes including cognition, neuronal changes and pathological markers.

These studies are useful for generating hypotheses about potential molecular pathways, but they do not demonstrate that P21 is an effective or approved treatment for Alzheimer’s disease or any other neurodegenerative condition.

P21 and Blood-Brain Barrier Research

The blood-brain barrier (BBB) presents a significant challenge when researchers develop molecules intended to influence the central nervous system. Large proteins such as CNTF have limited ability to cross the BBB efficiently.

P021 was designed with an adamantane-containing modification intended to improve properties relevant to central nervous system access. Scientific reviews describe the addition of an adamantylated glycine group as part of the development strategy for P021.

This structural modification is an important part of P21 research because it illustrates how chemical changes can be used to investigate the relationship between peptide structure and central nervous system availability.

Potential Research Applications of P21

Qualified laboratories may investigate P21 across several areas of experimental neuroscience, including:

Neurogenesis research: Studying proliferation and differentiation of neural progenitor cells.
Hippocampal biology: Investigating cellular processes associated with adult hippocampal neurogenesis.
Neurotrophic signalling: Examining pathways associated with CNTF and other neurotrophic factors.
BDNF research: Investigating changes in BDNF-related signalling and expression.
Synaptic plasticity: Studying molecular markers associated with adaptive changes in neural connections.
Neuronal differentiation: Examining the transition of progenitor cells towards neuronal phenotypes.
Cognitive research: Investigating relationships between molecular changes and behavioural outcomes in animal models.
Neurodegenerative research: Studying experimental models of neurodegenerative pathology.
Peptide engineering: Investigating how structural modifications influence peptide properties.
Analytical research: Characterising peptide identity, purity and molecular properties.

P21 Chemical Characteristics

P21 is a small synthetic compound derived from a biologically active CNTF fragment. The referenced Core Peptides listing identifies its molecular formula as C₃₀H₅₄N₆O₅, molecular weight as approximately 578.3 g/mol, and sequence as Ac-DGGL-adamatanylglycine-NH₂.

Scientific literature describes P021 as an adamantylated derivative of the shortened CNTF-derived sequence, highlighting the importance of the adamantane-containing modification in the development of the compound.

Because supplier nomenclature and chemical descriptions can differ, researchers should verify the exact molecular identity and batch information using analytical documentation before commencing an experiment.

P21 Compared With CNTF

Characteristic	P21 / P021	CNTF
Molecular Type	Small synthetic peptide derivative	Neurotrophic cytokine/protein
Research Focus	Neurogenesis, neurotrophic signalling and plasticity	Neuronal survival, differentiation and neurotrophic signalling
Structure	Short modified peptide	Much larger protein
BBB Research Interest	Designed with structural features intended to improve CNS access	Limited BBB penetration is an important research consideration
Research Status	Preclinical research compound	Established biological signalling protein

The development of P021 illustrates how researchers can identify an active region within a larger biological protein and modify a smaller peptide to investigate selected signalling properties.

P21 and P6 Research

P21 originated from research into smaller neurotrophic fragments of CNTF. An 11-amino-acid sequence referred to as Peptide 6 was first identified, followed by investigation of a shorter active sequence known as Peptide 6c.

Researchers subsequently incorporated an adamantylated glycine residue into the shortened structure, producing P021. This development process was intended to improve characteristics relevant to peptide stability and central nervous system activity.

The progression from CNTF to P6, P6c and P021 is of particular interest to peptide researchers because it demonstrates a structure-guided approach to developing small neurotrophic mimetics.

Research Evidence and Limitations

P21 is an interesting but preclinical research compound. Published literature has reported promising findings in animal models, including effects on neurogenesis, synaptic markers and cognition.

However, available evidence does not establish that these effects translate to humans. Recent research summaries report that P021 has not undergone established human clinical testing and has no authorised therapeutic indication.

There is also an important naming consideration: P21/P021 is distinct from p21/CDKN1A, a cell-cycle regulatory protein involved in processes including cell-cycle arrest and senescence. Researchers should use the full compound designation and analytical identity when documenting experiments to avoid confusion.

Frequently Asked Questions About P21 (5mg)

What is P21?

P21, also known as P021, is a synthetic peptide derivative developed from a biologically active region of ciliary neurotrophic factor (CNTF). It has been investigated primarily in preclinical neuroscience research.

How much P21 is supplied?

The referenced Core Peptides product contains 5mg of P21 in lyophilised powder form.

What is P021?

P021 is another designation for the research compound commonly marketed as P21. The P021 designation is useful for distinguishing the compound from the unrelated p21/CDKN1A protein.

Is P21 the same as p21/CDKN1A?

No. P21/P021 refers to a synthetic CNTF-derived peptide research compound, whereas p21/CDKN1A is a naturally occurring cell-cycle regulatory protein. They are chemically and biologically distinct.

What is P21 studied for?

Research has examined P21 in relation to neurogenesis, neuronal differentiation, synaptic plasticity, BDNF-related signalling, learning and memory, and experimental neurodegenerative disease models.

Does P21 cross the blood-brain barrier?

P021 was designed with an adamantane-containing modification intended to improve properties relevant to central nervous system access. Experimental research has investigated its activity in the brain, but this should not be interpreted as evidence of established human pharmacokinetics.

Has P21 been clinically proven to improve cognition?

No. Cognitive effects reported in the literature are primarily from animal research. There is insufficient human evidence to establish P21 as a cognitive-enhancement treatment.

Has P21 been approved as a medicine?

No. P21/P021 remains a research compound and does not have an established authorised therapeutic indication. Current evidence is predominantly preclinical.

Is P21 intended for human consumption?

No. The referenced Core Peptides product is designated for research, laboratory and analytical purposes only. It should not be represented as a medicine, supplement or product intended for human consumption.

What is the stated purity of P21 (5mg)?

The Core Peptides listing states a purity of >99%. Researchers should consult the batch-specific certificate of analysis for definitive analytical information about an individual product lot.

P21 (5mg) Research Summary

P21 (5mg), also known as P021, is a synthetic CNTF-derived peptide research compound investigated primarily in experimental neuroscience. Its development involved identifying a biologically active CNTF fragment and modifying the resulting short peptide with an adamantane-containing component.

Preclinical studies have explored P21 in relation to hippocampal neurogenesis, neuronal differentiation, synaptic plasticity, BDNF-related signalling and cognitive performance in animal models. These findings have made P021 an interesting subject for research into neurotrophic mechanisms and neurodegenerative disease biology.

At the same time, the current evidence should be interpreted carefully. P21 has not been established as a human therapeutic, and preclinical findings cannot be assumed to predict clinical efficacy or safety.

For qualified laboratories, P21 (5mg) can provide a defined research material for investigating peptide-mediated neurotrophic signalling, neural progenitor biology, hippocampal processes and related experimental pathways.

Research-Use Disclaimer

P21 (5mg) is intended exclusively for research, laboratory, analytical and in-vitro experimental purposes. It is not intended for human or animal consumption, self-administration, diagnosis, treatment, cure or prevention of any disease.

Any statements concerning neurogenesis, cognition, memory, neuroprotection or neurodegenerative disease refer to experimental research and should not be interpreted as established medical claims.

Researchers should verify the exact identity, purity and batch-specific analytical data using the applicable certificate of analysis and conduct all experimental work in accordance with relevant legislation, institutional requirements and appropriate laboratory safety procedures.

For research use only. Human and animal consumption prohibited.

Reviews

There are no reviews yet.